» Articles » PMID: 13575682

An Alternative Mechanism for the Properdin System

Overview
Journal J Exp Med
Date 1958 Oct 1
PMID 13575682
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence is presented that phenomena ascribed to the properdin system may be explained in terms of classical antibody (Ab) in combination with three of the components of complement (C'), i.e., C'(1), C'(4), and C'(2) respectively. The results suggest that the complex of properdin (P) with zymosan (Z) represents a mixture of Z.Ab, Z.Ab.C'(1, 4), Z.Ab-C'(1, 4, 2), and Z.Ab.C'(1, 4, 2) in a decayed state. The purported preferential reactivity of Z with the third component of C' (C'(3)) is not supported by the present experiments in which Z was reacted with C' in both guinea pig and human sera. Approximately the same number of reactive units of C'(1, 4) and of C'(3) were inactivated by Z, as well as by D. pneumoniae and a washed specific precipitate of bovine albumin-anti-albumin. The latter evidence that small amounts of antigen-antibody complex fix significant amounts of C'(3) stands in contrast with the classical concept that C'(3) is not fixed in ordinary complement fixation reaction. The observed reactivity of C'(3) is explained on the basis of the present use of essentially undiluted serum as a source of C'(3) and of 37 degrees as the temperature for fixation. Ancillary data indicate that purified properdin contains Ab. In the presence of a chelating agent and at 0 degrees properdin agglutinated Z granules. Measurements of nitrogen (N) uptake by Z suggest that 0.25 microg. N were contributed by solutions stated to contain 1 unit of properdin. The broad spectrum of reactivity or cross-reactivity of the Ab in normal serum is likely due to the wide distribution in nature of closely related polysaccharides. Further immunochemical studies are necessary to establish definitively the origin and mode of action in "natural resistance" of antibodies reactive with these polysaccharides.

Citing Articles

Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement.

Zhang J, Song L, Pedersen D, Li A, Lambris J, Andersen G Elife. 2020; 9.

PMID: 32909942 PMC: 7511233. DOI: 10.7554/eLife.60908.


The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?.

Harrison R Semin Immunopathol. 2017; 40(1):15-35.

PMID: 29167939 DOI: 10.1007/s00281-017-0661-x.


Quantitative Modeling of the Alternative Pathway of the Complement System.

Zewde N, Gorham Jr R, Dorado A, Morikis D PLoS One. 2016; 11(3):e0152337.

PMID: 27031863 PMC: 4816337. DOI: 10.1371/journal.pone.0152337.


RELATION OF A beta(1)-GLYCOPROTEIN OF HUMAN SERUM TO THE COMPLEMENT SYSTEM.

MULLER-EBERHARD H, Nilsson U J Exp Med. 2009; 111(2):217-34.

PMID: 19867170 PMC: 2137252. DOI: 10.1084/jem.111.2.217.


Properdin: New roles in pattern recognition and target clearance.

Kemper C, Hourcade D Mol Immunol. 2008; 45(16):4048-56.

PMID: 18692243 PMC: 2628304. DOI: 10.1016/j.molimm.2008.06.034.


References
1.
PILLEMER L, Blum L, Lepow I, Ross O, Todd E, Wardlaw A . The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954; 120(3112):279-85. DOI: 10.1126/science.120.3112.279. View

2.
Levine L, Mayer M . Kinetic studies on immune hemolysis. V. Formation of the complex EAC'x and its reaction with C'y. J Immunol. 1954; 73(6):426-34. View

3.
HINZ Jr C, JORDAN Jr W, PILLEMER L . The properdin system and immunity. IV. The hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1956; 35(5):453-7. PMC: 438830. DOI: 10.1172/JCI103296. View

4.
Cordoba F, Heidelberger M . Cross-reactions of antityphoid and antiparatyphoid B horse sera with various polysaccharides. J Exp Med. 1956; 104(3):375-82. PMC: 2136573. DOI: 10.1084/jem.104.3.375. View

5.
HERBUT P, KRAEMER W . The possible role of the properdin system in transplantable cancer; the effect of zymosan on transplantable human carcinoma. Cancer Res. 1956; 16(11):1048-52. View